Sirius Genomics Announces Change in Leadership

VANCOUVER, December 8 - Sirius Genomics, a developer of pharmacogenomic diagnostics, announced
today that Chris Wagner has been appointed President and Chief Executive
Officer, replacing Dr. Brad Popovich.

"We want to thank Brad for his strong leadership as President and CEO
over the last four years. Brad has taken the Company from discovery to the
commercialization phase in a very short period of time. Brad has also managed
to recruit one of the best management teams I have seen in the companion
diagnostic space," stated Dr. Heiner Dreismann, member of the Sirius Genomics
Board of Directors.

Dr. Popovich will continue as member of Sirius Genomics Board and will
continue to assist Mr. Wagner and the Company with the provision of strategic
advice and support.

"The Sirius Board of Directors believes that this is the right time to
make this transition in the evolution of the Company because we have
initiated our validation studies on our Xigris Diagnostic and we are
spending more time on commercialization and partnership initiatives.
Mr. Wagner's extensive background in global pharmaceutical and diagnostic
commercialization and partnering are the skills needed to move the Xigris
Diagnostic forward from here. The Sirius Board appreciates the efforts of
both Chris and Brad in making this transition so smooth and seamless,"
stated Dr. Jim McEwen, Chairman of the Board.

Chris Wagner has over 17 years of experience in marketing, sales and
business development. Since 2007, Mr. Wagner was Vice President of Business
Development at Sirius Genomics. Previously, Mr. Wagner was with Aspreva
Pharmaceuticals as the Vice President of Marketing and Vice President of
Business Development. Prior to Aspreva, Mr. Wagner was with Eli Lilly as an
international service employee working in Europe, North America and Asia with
positions based in Toronto, Indianapolis and Boston. Mr. Wagner holds a BSc
in Organic Chemistry from the University of British Columbia.

About Sirius Genomics: www.siriusgenomics.com

Sirius Genomics is a drug-enabling company that develops pharmacogenomic
(PGx) diagnostics that lead to better patient outcomes through personalized
medicine. Sirius generates value by improving the safety and effectiveness of
pharmaceutical compounds. The Company correlates patient genetics with
clinical outcomes, leading to proprietary and commercially viable PGx
products that enable better drug treatment. The Company's first product
is a genetic predictor of response to treatment for sepsis, a severe blood
infection.

This release contains forward-looking statements that are not based on
historical fact. These forward-looking statements involve risks,
uncertainties and other factors that may cause the actual results, events
or developments to be materially different from those expressed or implied
by such forward-looking statements. Readers are cautioned not to place
undue reliance on such forward-looking statements.

For further information: Chris Wagner, President and CEO, Sirius
Genomics, +1-(604)-484-7195

For further information: Chris Wagner, President and CEO, Sirius Genomics, +1-(604)-484-7195